Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (43)	5/28/1999 5:29:00 PM
From: JFitnich	Respond to of 447

That's interesting since I remember reading that the # of biotech analysts have dropped in half since '97. I imagine there will always be other opportunities besides the sell-side though. Maybe venture capital. Appreciate the info. King also started or picked up coverage on a couple of others including VIRS and PGNX (which was Mark Simon's at BBRS and his own at Vector I believe). I also see that BBRS was an underwriter on the new Trimeris offering, so maybe we'll see something there. I'll stop cluttering up the OSIP board now. Enjoy the Memorial Day weekend! JF